Tyra Biosciences, Inc.(TYRA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
TYRA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Tyra Biosciences, Inc. (TYRA), a Healthcare sector company. TYRA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Tyra Biosciences, Inc. reports net income of $-45.6M, free cash flow of $-31.1M. Top institutional holders of TYRA by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., FMR, Jupiter Topco, based on the most recent SEC filings. TYRA trades on the Nasdaq exchange and files with the SEC under CIK 1863127. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TYRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tyra Biosciences, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-45.6M
Free Cash Flow
Q2 2026
$-31.1M
ROIC
Q2 2026
-55.4%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-38.7% YoYOperating Income
-27.4% YoYEPS (Diluted)
-33.1% YoYTotal Assets
-22.3% YoYOp. Cash Flow
-36.4% YoYFree Cash Flow
-35.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-119.9M -38.7% | $-86.5M -25.1% | $-69.1M -25.0% | $-55.3M -110.4% | $-26.3M -181.6% | $-9.3M |
| Operating Income | $-132.8M -27.4% | $-104.2M -30.3% | $-79.9M -35.7% | $-58.9M -124.2% | $-26.3M -182.8% | $-9.3M |
| EPS (Diluted) | $-2.01 -33.1% | $-1.51 +6.8% | $-1.62 -22.7% | $-1.32 +30.9% | $-1.91 | — |
| Total Assets | $282.6M -22.3% | $363.6M +61.0% | $225.9M -15.1% | $266.2M -13.2% | $306.7M +1815.6% | $16.0M |
| Operating Cash Flow | $-95.1M -36.4% | $-69.8M -39.2% | $-50.1M +0.3% | $-50.3M -111.8% | $-23.7M -205.9% | $-7.8M |
| Free Cash Flow | $-95.3M -35.3% | $-70.4M -38.4% | $-50.9M -0.1% | $-50.8M -108.3% | $-24.4M -202.2% | $-8.1M |
Get alerted when TYRA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Tyra Biosciences, Inc. including:
Top Institutional Holders of TYRA
RA CAPITAL MANAGEMENT, L.P.
$389.6M12,198,625 shFMR LLC
$284.9M8,920,513 shJupiter Topco LLC
$139.2M4,352,448 shAlta Partners Management Company, L.P.
$122.1M3,823,425 shNextech Invest, Ltd.
$113.5M3,553,585 shTCG Crossover Management, LLC
$103.8M3,248,980 shBlackRock, Inc.
$96.8M3,031,972 shPRICE T ROWE ASSOCIATES INC /MD/
$88.9M2,782,567 shSTATE STREET CORP
$68.4M2,140,368 shCommodore Capital LP
$59.9M1,875,000 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $389.6M | 12,198,625 |
| FMR LLC | $284.9M | 8,920,513 |
| Jupiter Topco LLC | $139.2M | 4,352,448 |
| Alta Partners Management Company, L.P. | $122.1M | 3,823,425 |
| Nextech Invest, Ltd. | $113.5M | 3,553,585 |
| TCG Crossover Management, LLC | $103.8M | 3,248,980 |
| BlackRock, Inc. | $96.8M | 3,031,972 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $88.9M | 2,782,567 |
| STATE STREET CORP | $68.4M | 2,140,368 |
| Commodore Capital LP | $59.9M | 1,875,000 |
More Healthcare Companies
View all Healthcare →Put TYRA on your watchlist
Track score changes the day Tyra Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TYRA a good stock to buy?
13F Pro's AI-powered analysis of Tyra Biosciences, Inc. (TYRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TYRA are available on the TYRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TYRA is classified as a small company.
Which hedge funds own TYRA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TYRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Tyra Biosciences, Inc.'s investment landscape.